Evaluation of Prostate Cancer with PET/MRI.
In the ongoing effort to understand and cure prostate cancer, imaging modalities are constantly evolving to assist in clinical decisions. Multiparametric MRI can be used to direct prostate biopsies, improve diagnostic yield, and help clinicians make more accurate decisions. PET is superior in providing biologic information about the cancer and is sensitive and highly specific. Integrated PET/MRI is a welcome technical advance with great potential to influence the diagnosis and management of prostate cancer in clinical practice.
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland liza.lindenberg@mail.nih.gov.
Liza
L
Lindenberg
Department of Radiology and Imaging Sciences, National Institutes of Health Clinical Center, Bethesda, Maryland; and.
Mark
M
Ahlman
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Baris
B
Turkbey
Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins Medical Institutions, Baltimore, Maryland.
Esther
E
Mena
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Peter
P
Choyke
D000818:Animals; D019317:Evidence-Based Medicine; D006801:Humans; D007089:Image Enhancement / Q000379:methods*; D007090:Image Interpretation, Computer-Assisted; D008279:Magnetic Resonance Imaging; D008297:Male; D064847:Multimodal Imaging; D049268:Positron-Emission Tomography; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging*
PET/MRI; multiparametric MRI; prostate cancer
J Nucl Med. 2014 May;55(5):724-9
24652827
J Nucl Med. 2012 Apr;53(4):538-45
22343504
Eur J Nucl Med Mol Imaging. 2014 Jan;41(1):79-88
24085502
J Urol. 2014 Dec;192(6):1642-8
25117476
J Urol. 2015 Feb;193(2):466-72
25150643
J Nucl Med. 2006 Feb;47(2):287-97
16455635
Semin Nucl Med. 2015 May;45(3):192-200
25841274
Urology. 2016 Feb;88:125-34
26680244
Acta Oncol. 2016;55(1):59-67
25833330
J Urol. 2007 Sep;178(3 Pt 2):S14-9
17644125
J Nucl Med. 2012 May;53(5):796-804
22505568
Skeletal Radiol. 2014 Nov;43(11):1503-13
24841276
CA Cancer J Clin. 2016 Jul;66(4):326-36
26594835
Radiology. 2002 Jul;224(1):203-10
12091684
Eur Urol. 2016 Aug;70(2):233-45
26215604
Radiology. 2008 Dec;249(3):1017-25
18849502
Eur Urol. 2012 Nov;62(5):902-9
22325447
Radiology. 2007 Apr;243(1):28-53
17392247
J Nucl Med. 2016 Mar;57(3):367-71
26585062
Eur J Nucl Med Mol Imaging. 2014 May;41(5):887-97
24352789
J Nucl Med. 2016 Jan;57(1):46-53
26493203
Nucl Med Commun. 2015 Dec;36(12):1165-73
26397999
Urol Oncol. 2015 Oct;33(10):425.e1-425.e6
26259666
Radiology. 2007 Oct;245(1):176-85
17717328
Eur J Nucl Med Mol Imaging. 2016 Jan;43(1):70-83
26508290
Clin Chem Lab Med. 2014 May;52(5):725-33
24310773
Eur J Nucl Med Mol Imaging. 2012 Jun;39(6):1085-6
22310854
Eur J Nucl Med Mol Imaging. 2015 Jan;42(1):42-8
25112399
Urol Oncol. 2013 Feb;31(2):144-54
22658884
J Endourol. 2014 Nov;28(11):1283-9
25010361
J Nucl Med. 2015 Jul;56(7):1003-1010
26069305
J Nucl Med. 2016 Mar;57(3):420-30
26742709
Prostate Cancer Prostatic Dis. 2015 Jun;18(2):128-36
25644248
Eur Urol. 2008 Aug;54(2):371-81
18395322
J Nucl Med. 2012 Jun;53(6):845-55
22534830
Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):e787-93
22331003
Mol Imaging Biol. 2015 Oct;17(5):595-608
26286794
Radiology. 2013 Aug;268(2):461-9
23579051
Radiology. 2013 Dec;269(3):857-69
24009348
Radiology. 2014 Dec;273(3):859-69
25102372
Eur J Nucl Med Mol Imaging. 2010 Jun;37(6):1106-16
20306038
Radiology. 2014 Oct;273(1):220-31
24877983
JAMA. 2015 Jan 27;313(4):390-7
25626035
Eur J Nucl Med Mol Imaging. 2013 Oct;40(10):1486-99
23817684
Clin Cancer Res. 2011 Dec 15;17(24):7645-53
22042970
J Nucl Med. 2014 Jan;55(1):88-94
24337608
Urol Int. 2014;92(3):294-9
24296943
Eur Urol. 2016 Nov;70(5):829-836
26795686
Eur J Nucl Med Mol Imaging. 2012 Jul;39(7):1154-60
22526955
Tomography. 2015 Sep;1(1):18-22
26726317